SCHEMBL5576840

SCHEMBL5576840

c1ccc2c(c1)cnc1c[nH]cc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
GPR3 P46089 1/20 0.61
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP3A4 P08684 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
MAPK1 P28482 1/20 0.37
PARP1 P09874 1/20 0.37
PRKCI P41743 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthridine SCHEMBL9106884 0.76 GPR3 (1.00) KDM4EGPR3NPC1LMNAMAPT
Phenanthridine SCHEMBL8666 0.76 GPR3 (1.00) KDM4EGPR3NPC1LMNAMAPT
Phenanthridine SCHEMBL30914262 0.76 GPR3 (1.00) KDM4EGPR3NPC1LMNAMAPT
Phenanthridine SCHEMBL30823553 0.76 GPR3 (1.00) KDM4EGPR3NPC1LMNAMAPT
SCHEMBL1920533 0.76 GPR3 (0.61) KDM4EGPR3MAPTSMN1; SMN2CYP3A4
SCHEMBL29779877 0.76 GPR3 (0.61) KDM4EGPR3MAPTSMN1; SMN2CYP3A4
Phenanthridine SCHEMBL7108915 0.74 GPR3 (0.77) KDM4EGPR3NPC1LMNAMAPT
SCHEMBL27816324 0.74 GPR3 (0.59) KDM4EGPR3MAPTSMN1; SMN2CYP3A4
Phenanthridine SCHEMBL23003530 0.74 GPR3 (0.95) KDM4EGPR3NPC1LMNAMAPT
SCHEMBL2680789 0.74 KDM4E (0.71) KDM4EGPR3NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS Frequency Therapeutics, Inc. (US) 2022-05-05 US disclosed
EP-1778225-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS Bristol-Myers Squibb Company (US) 2007-05-02 EP disclosed
WO-2006019886-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed
EP-0888347-A1 PHARMACEUTICALLY USEFUL COMPOUNDS Astra Pharmaceuticals Limited (GB) 1999-01-07 EP disclosed
WO-1997034893-A1 PHARMACEUTICALLY USEFUL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS WNT3A, WNT1, WNT3 KDM4E 853/4885GPR3 319/4885NPC1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.